🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Essential Thrombocythemia

    phase 2 small molecule terminated

    1 trial

  2. Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD

    Mineralys Therapeutics

    Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  3. Lotilaner Gel, 2.0%

    Tarsus Pharmaceuticals

    Papulopustular Rosacea

    phase 2 small molecule completed

    1 trial

  4. Low Dose TP-05

    Tarsus Pharmaceuticals

    Healthy Volunteer

    phase 2 small molecule completed

    1 trial

  5. Low dose of MRM-3379

    Mirum Pharmaceuticals International B.V.

    Fragile X Syndrome

    phase 2 small molecule active

    1 trial

  6. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Extensive-stage Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  8. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Advanced Soft-tissue Sarcoma

    phase 2 small molecule active

    1 trial

  9. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  10. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Small Cell Lung Cancer ( SCLC )

    phase 2 small molecule active

    1 trial

  11. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Refractory Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  12. Lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Locally Advanced Soft Tissue Sarcoma

    phase 2 small molecule terminated

    1 trial

  13. Lurbinectedin 4 MG Injection [Zepzelca]

    Jazz Pharmaceuticals Ireland Limited

    Gastrointestinal Malignancies

    phase 2 small molecule completed

    1 trial

  14. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  15. Lutikizumab, USP/Ph. Eur.ABBV-323, Universal Placebo (Lutikizumab, Ravagalimab)

    AbbVie Deutschland GmbH & Co. KG

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  16. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  17. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  18. Lysergide D-tartrate, Placebo for Lysergide tartrate oral solution

    Disc Medicine

    Chronic cluster headache

    phase 2 small molecule active

    1 trial

  19. MAS825, -

    Novartis Pharmaceuticals

    Still’s disease

    phase 2 small molecule active

    1 trial

  20. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  21. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  22. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  23. MBG453, VENETOCLAX, VENETOCLAX, AZACITIDINE, VENETOCLAX

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  24. MD-0727

    IRONWOOD PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources